Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 32 Seiten
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers(16), H. 15 - ISSN 2072-6694
In: © 2024 by the authors., Basel
- Ereignis
-
Veröffentlichung
- (wo)
-
Jena
- (wer)
-
Friedrich-Schiller-Universität Jena
- (wann)
-
2024
- Urheber
- DOI
-
10.3390/cancers16152635
- URN
-
urn:nbn:de:101:1-2409110214472.474271144979
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:47 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cai, Alvan
- Chen, Yuan
- Wang, Lily S.
- Cusick, John K.
- Shi, Yihui
- Friedrich-Schiller-Universität Jena
Entstanden
- 2024
Ähnliche Objekte (12)
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Evaluation of molecular prognostic markers for premenopausal patients with HR+/HER2− early breast cancer
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Evaluation of molecular prognostic markers for premenopausal patients with HR+/HER2− early breast cancer
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Evaluation of molecular prognostic markers for premenopausal patients with HR+/HER2− early breast cancer
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy